Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03546894 · ClinicalTrials.gov registry record
A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors
A clinical trial, sponsored by Takeda.
- Completed
- Registry status
- 111
- Enrollment target
NCT03546894 is a clinical trial that has completed, run by Takeda. The registered enrollment target is 111 participants.
The verdict
NCT03546894 has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- 111 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the differences in PFS for participants who have been receiving brigatinib as ALK inhibitor therapy for ALK+NSCLC compared to those participants receiving alectinib, ceritinib, lorlatinib, or other ALK inhibitors that may become available during study treatment.
Interventions
- DRUG Lorlatinib
- DRUG Alectinib
- DRUG Ceritinib
- DRUG Brigatinib
- DRUG Any FDA Approved ALK Inhibitors
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2018-07-23 |
| Est. Completion | 2023-02-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03546894
The ClinicalTrials.gov registry entry for NCT03546894 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Lorlatinib is the first listed.
NCT03546894 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03546894 about?
NCT03546894 is a clinical study titled "A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors". The primary purpose of this study is to determine the differences in PFS for participants who have been receiving brigatinib as ALK inhibitor therapy for ALK+NSCLC compared to those participants receiving alectinib, ceritinib, lorlatinib, or other ALK inhibitors that may become available during stud...
What is the current status of trial NCT03546894?
This trial is currently completed. The enrollment target is 111 participants. The study started on 2018-07-23. Estimated completion is 2023-02-13.
What interventions are being tested in trial NCT03546894?
The interventions under investigation include: Lorlatinib (DRUG), Alectinib (DRUG), Ceritinib (DRUG), Brigatinib (DRUG), Any FDA Approved ALK Inhibitors (DRUG).
Who is sponsoring clinical trial NCT03546894?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.